Sym 021

Drug Profile

Sym 021

Alternative Names: Sym021

Latest Information Update: 01 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Symphogen
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Programmed cell death 1 ligand 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 21 Apr 2018 Pharmacodynamics data from preclinical studies in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 01 Nov 2017 Phase-I clinical trials in Solid tumours and Lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT03311412)
  • 17 Oct 2017 Symphogen plans a phase I trial for Solid tumours and Lymphoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy) in USA and Canada in November 2017 (NCT03311412)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top